Scarica l'app Stockscreener
2.06
4.57%
0.09
Dopo l'orario di chiusura:
2.13
0.07
+3.40%
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com
Research Analysts Offer Predictions for TNYA FY2024 Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings - MarketBeat
William Blair Brokers Increase Earnings Estimates for TNYA - MarketBeat
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat
Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Piper Sandler raises confidence in Tenaya Therapeutics stock ahead of December data, reiterates Overweight rating - Investing.com Australia
Tenaya shares retain stock target, buy rating on safety milestone - Investing.com
Tenaya shares hold buy rating, positive outlook on trial progress - Investing.com
Tenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at Canaccord Genuity Group - MarketBeat
Leerink sees Tenaya's trial update as positive, maintains price target By Investing.com - Investing.com UK
Tenaya stock undervalued despite strong Ph1 safety update, says Canaccord - Investing.com
Tenaya (TNYA) Experiences Notable Stock Increase Following Key Update - Stocks Telegraph
Tenaya shares hold buy rating, positive outlook on trial progress By Investing.com - Investing.com UK
Tenaya advances gene therapy trial for heart condition - Investing.com
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire
SVP, Accounting and Fin. Ops. Saito Chihiro sold 2,363 shares of Tenaya Therapeutics Inc [TNYA] - Knox Daily
Tenaya Therapeutics stock hits 52-week low at $1.63 By Investing.com - Investing.com Canada
Technical analysis of Tenaya Therapeutics Inc (TNYA) stock chart patterns - US Post News
A Closer Look at Tenaya Therapeutics Inc (TNYA) Stock Gains - The InvestChronicle
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Hypertrophic Cardiomyopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing - Barchart
Charting the Course: Tenaya Therapeutics Inc’s TNYA Stock Prospects - The InvestChronicle
Tenaya Therapeutics Inc (TNYA) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Daily Progress: Tenaya Therapeutics Inc (TNYA) Drop -3.11, Closing at 1.87 - The Dwinnex
Tenaya Therapeutics Inc [TNYA] Insider Activity: An Update for Investors - Knox Daily
Canaccord keeps buy rating, price target on Tenaya shares - Investing.com
Tenaya Therapeutics' SWOT analysis: gene therapy stock poised for pivotal catalysts By Investing.com - Investing.com South Africa
Tenaya Therapeutics' SWOT analysis: gene therapy stock poised for pivotal catalysts - Investing.com India
Myocardial Infarction Global Market Report 2024 Size and Forecast - WhaTech
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
A closer look at Tenaya Therapeutics Inc (TNYA)’s stock price trends - US Post News
Owning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA), - Yahoo Finance
Rocket Pharmaceuticals Maxes Out Recruitment in Pivotal Trial for Danon Disease Gene Therapy RP-A501 - CGTLive™
Recent Insider Activity Could Benefit Tenaya Therapeutics Inc (TNYA) - Knox Daily
Tenon Medical Inc (TNON) expanding its growth trajectory ahead - SETE News
Tenet Healthcare Corp. (THC) Stock: A Year of Market Fluctuations - The InvestChronicle
Daily Market Movement: Tenon Medical Inc (TNON) Sees a -18.94 Decrease, Closing at 6.25 - The Dwinnex
Choreo LLC Invests $335,000 in Tenet Healthcare Co. (NYSE:THC) - Defense World
Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World
TELA’s latest rating updates from top analysts. - Knox Daily
Tenet Healthcare (NYSE:THC) Stock Price Down 2.3% - MarketBeat
Nothing is Better Than Tenaya Therapeutics Inc (TNYA) stock at the moment - SETE News
Closing Bell Recap: TELA Bio Inc (TELA) Ends at 2.49, Reflecting a -6.04 Downturn - The Dwinnex
Tenaya Therapeutics reshuffles board, introduces new equity plan By Investing.com - Investing.com Australia
Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - AccessWire
Financial Health Report: Tenaya Therapeutics Inc (TNYA)’s Ratios Tell a Tale - The Dwinnex
Teekay Tankers Ltd. (NYSE:TNK) Shares Sold by Daiwa Securities Group Inc. - Defense World
Los Angeles Capital Management LLC Acquires Shares of 27,772 TELA Bio, Inc. (NASDAQ:TELA) - Defense World
American Century Companies Inc. Buys 93,788 Shares of Teekay Tankers Ltd. (NYSE:TNK) - Defense World
Tenaya Therapeutics reshuffles board, introduces new equity plan - Investing.com
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):